USA flag logo/image

An Official Website of the United States Government

PDZ-targeted Therapeutics for Cervical Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95856
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA137935
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
ARBOR VITA CORPORATION
6611 Dumbarton Circle FREMONT, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: PDZ-targeted Therapeutics for Cervical Cancer
Agency: HHS
Contract: 1R43CA137935-01A2
Award Amount: $208,622.00
 

Abstract:

DESCRIPTION (provided by applicant): Oncogenic variants of human papilloma virus (HPV) have been correlated with cervical cancer at a frequency of gt 99%, and also cause penile, anal and head and neck cancers. We have recently determined that all oncogeni c E6 proteins bind to the first PDZ domain of MAGI1 protein, an interaction that is critical for both HPV-induced carcinogenesis and for maintenance of the cancerous state in HPV-positive cells. We have identified a novel lead small molecule inhibitor (AVC -7) of the interaction between E6 oncoprotein and MAGI1- PDZ1. Interruption of the E6 / MAGI1-PDZ1 interaction results in down regulation of E6 and E7 oncoproteins, restoration of the tumor suppressor p53, and induction of apoptosis in cervical cancer cell lines. In this grant, Arbor Vita proposes to identify more potent derivatives of AVC-7 and to demonstrate the efficacy of these derivatives in treatment of cervical cancer in vitro and in vivo. Specifically, Arbor Vita proposes to (1) Design derivatives o f AVC-7 with increased potency in binding to MAGI1 and improved water solubility, (2) Demonstrate the selective biological activity of AVC-7 derivatives in cultured HPV-positive cervical cancer cells, and (3) Demonstrate efficacy of the most promising comp ound in a murine xenograft tumor model. Successful completion of the grant will result in a 10 mM (or better) inhibitor of the E6 / MAGI1-PDZ1 interaction that selectively induces apoptosis in HPV-positive cancer cells and significantly decreases tumor gro wth in the murine xenograft model. This proposal will be followed by a Phase 2 application to advance a lead compound towards human clinical testing via PK/PD studies, GLP toxicology studies, and GMP drug manufacturing and formulation. PUBLIC HEALTH RELEVANCE: HPV-related cancers such as cervical, anal, penile, and head and neck are serious disorders that affect hundreds of thousands of people and for which there are no approved drugs directed at the underlying cause. Arbor Vita has characterized a novel target of the oncogenic HPV E6 proteins named MAGI1, and has identified early lead drugs that can reduce levels of cancer causing E6 oncoproteins while restoring levels of the p53 tumor suppressor. p53 is a key protein that protects cells from becom ing cancerous.

Principal Investigator:

Michael P. Belmares
4085853900
MICHAEL.BELMARES@ARBORVITA.COM

Business Contact:

Johannes Schweixer
johannes.schweizer@arborvita.com
Small Business Information at Submission:

ARBOR VITA CORPORATION
6611 Dumbarton Circle Fremont, CA 94555

EIN/Tax ID: 177048381
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No